Skip to main content

Table 3 Baseline characteristics of the study population

From: Immune monitoring after pediatric liver transplantation – the prospective ChilSFree cohort study

Subjects n (%) / median (range)
Sex
 Male 142 (56%)
 Female 112 (44%)
Age 2.5 years (0.2–18.0)
 Diagnosis
 Biliary atresia 101 (39.8%)
 Malignant liver disease 24 (9.4%)
 Metabolic liver disease 21 (8.3%)
 Acute liver failure 10 (3.9%)
 PSC 7 (2.8%)
 PFIC 12 (4.7%)
 Alagille syndrome 11 (4.3%)
 Cystic fibrosis 11 (4.3%)
 Wilson’s disease 4 (1.6%)
 Congenital hepatic fibrosis 3 (1.2%)
 Toxic liver damage 1 (0.4%)
 Other 49 (19.3%)
Type of graft
 Living related transplantation 73 (28.7%)
 Cadaveric transplantation 181 (71.3%)
ABO compatibility
 ABO compatible 241 (94.9%)
 ABO incompatible 13 (5.1%)
  1. Abbreviations: PSC primary sclerosing cholangitis, PFIC progressive familial intrahepatic cholestasis